BioCryst Pharmaceuticals, Inc. (BCRX)

NMS – Цена в реальном времени. Валюта: USD

8.80

+0.22 (2.56%)

При закрытии: May 12, 2026, 4:00 PM EDT

8.87

+0.07 (0.80%)

После закрытия: May 12, 2026, 7:40 PM EDT

07.05.2026

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.

06.05.2026

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

06.05.2026

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.06. This compares to break-even earnings per share a year ago.

06.05.2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —

05.05.2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

04.05.2026

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

28.04.2026

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

Видео

No Data

There is no data to display

Пресс-релизы

06.05.2026

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —

05.05.2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04.05.2026

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

06.04.2026

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —

BioCryst Pharmaceuticals, Inc. (BCRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioCryst Pharmaceuticals, Inc. (BCRX)

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Search stocks

BioCryst Pharmaceuticals, Inc. (BCRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioCryst Pharmaceuticals, Inc. (BCRX)

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst to Present at Upcoming Investor Conferences

Видео

No Data

Пресс-релизы

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer